No Data
No Data
BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $61
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Apellis Pharmaceuticals, Inc. (APLS): Among the Best Mid-Cap Healthcare Stocks To Buy Now
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Profit Outlook
No Data
108S OP : Best pharma stock to buy now